Navigation Links
S1P1 Lead Compounds, AMG 369 and AMG 277, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
Date:10/12/2011

WELLESLEY HILLS, Mass., Oct. 12, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, AMG 369 and AMG 277, will be offered December 8, 2011 in a sealed bid sale.

Some companies with S1P modulators in development currently are:  Novartis, Actelion, Lexicon, Pfizer, Ono Pharmaceuticals, Glaxo Smith Kline, Mitsubishi Tanabe Pharma, Receptos, Arena Pharmaceuticals, Exelixis, Boehringer Ingelheim, Biogen Idec, Kyorin, Angio, Apogee Biotechnology and Lpath.

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – jffinnjr@finnwarnkegayton.com or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  He has been involved in loan workouts and bankruptcy cases for 37 years.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@finnwarnkegayton.com<
'/>"/>

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
3. U.S. Appeals Court Reinstates Claim That Controversial Diet Drug Redux Should Never Have Been Offered to American People
4. Free Prostate Screenings Offered at Virginia G. Piper Cancer Center
5. Humana and Walmart Announce Innovative Medicare Part D Prescription Drug Plan with Lowest National Monthly Premium Offered in all 50 States and D.C. (1)
6. Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia
7. Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011
8. Exclusive Coverage for Kidney Dialysis Centers Offered by Five Star Healthcare
9. For Second Straight Year, Humana Walmart-Preferred Rx Plan (PDP) Features Lowest Monthly Premium Offered In All 50 States and Washington D.C.
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Calif. , July 29, 2015 Sangamo ... the company will release its second quarter 2015 financial ... 2015. The press release will be followed by a ... open to the public via telephone and webcast. During ... financial results and discuss other business matters. ...
(Date:7/29/2015)... 29, 2015 Alvarado Hospital unveiled its ... Alvarado Spine & Joint Institute. The institute is ... on spinal surgery and joint replacement. The Spine ... a patient experience-focused approach. For example, patients are ... in, rather than patient gowns. ...
(Date:7/29/2015)... July 29, 2015   Turing Pharmaceuticals AG ... joined the company as its first Chief Communication Officer. ... have overall responsibility for internal and external communications and ... He will report directly to Founder and Chairman, ... Leadership Team. "We are excited to have ...
Breaking Medicine Technology:Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast 2The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 3
... 8 Nektar,Therapeutics (Nasdaq: NKTR ) today ... program to evaluate NKTR-102 (PEG-irinotecan) as a,potential treatment ... using the company,s innovative small molecule,PEGylation technology platform., ... for NKTR-102 in colorectal cancer is,a major achievement ...
... Trial Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy ... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... publication of the INFUSE-LR clinical trial results in the Journal,of ...
Cached Medicine Technology:Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 2Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 3Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:7/29/2015)... ... 2015 , ... Abt Associates has named Selena Ramkeesoon, a ... In her position, Ramkeesoon will help build and expand work in communications, and ... to a decade at ICF International, most recently as a vice president. During ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the The Media ... and are exposed to advertisements, for medicinal use are more likely to abuse the ... the use of marijuana is considered beneficial are more apt to use the substance, ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may ... MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with ...
(Date:7/29/2015)... ... 29, 2015 , ... The NCCA re-accredited the Commission for ... 30, 2019, during its recent meeting. , The Commission received renewal of NCCA ... with the NCCA’s Standards for the Accreditation of Certification Programs. NCCA is ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... Michigan, changed its name in July to Kalamazoo Strength & Conditioning. , The ... , and “reflects the evolution of our training center over the past three ...
Breaking Medicine News(10 mins):Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4
... study has shown that those people who eat breakfast regularly ... The researchers found from the Children’s Hospital in Boston that ... per cent lower among people who ate breakfast compared to ... Insulin resistance syndrome is a disorder that includes// obesity, high ...
... reported by researchers in the Journal of Hypertension ... morbidity and improve their atherosclerotic risk profile by ... indicated that serum lipoprotein(a), a powerful predictor of ... The researchers studied 402 patients with untreated essential ...
... now much easier than earlier and according to James ... many people, both men and women are seeing plastic ... past, when patients would wait until they were 50 ... signs of aging. He also added that non-surgical treatments ...
... Drug Administration's(FDA) new effort to re-examine very old ... required proof that drugs worked well, has landed ... trouble. Until now FDA stressed that the expectorant, ... crackdown lead to the FDA formally approving sale ...
... Institute, led by Glenn Dranoff, MD,have reported in the ... vaccines made from patients' own tumors are safe and ... for deadly cancers. Researchers claim that the tumors grow ... immune system attacks -- ignore them. In the new ...
... for Preventing and Reversing Atherosclerosis in Houston, Texas, ... that intense lifestyle changes plus pharmacologic lipid treatment ... a greater extent than usual-care cholesterol lowering drugs. ... by performing myocardial perfusion imaging at baseline and ...
Cached Medicine News:Health News:New lung cancer vaccine on the anvil 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: